NPPA Fixes Ceiling Price Of 4 Scheduled Formulation, Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority(NPPA) has fixed the ceiling prices for the 4 scheduled formulations including Tenofovir Alafenamide Fumarate (TAF), Buprenorphine and etc. under Drugs (Prices Control) Order, 2013.
This came in line with the decisions of the 106th authority meeting dated 30.12.2022, where the ceiling price fixation of scheduled formulation under the Drugs (Price Control) Order,2013 ( National List of Essential Medicine 2022) was discussed.
Scheduled formulation means any formulation, included in the First Schedule whether referred to by generic versions or brand name (mainly products covered under National List of Essential Medicines are Scheduled Formulation). In other words, all medicines that are covered in National List of Essential Medicine, which are notified in Schedule 1, by the Govt. are scheduled formulation.
"Ceiling Price" refers to a price fixed by the Government for Scheduled Formulations in accordance with the provisions of drugs (prices control) order, 2013. Ceiling Price is the Maximum Price to Retailer (excluding Taxes, if any)for the given product.
The notice declared that in the exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May 2013 and S.O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
| Sl. No | Name of the Scheduled Formulation | Dosage form and Strength | Unit | Ceiling Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) |
| 1 | Buprenorphine (A) +Naloxone (B) | Tablet (Sub-lingual) 2mg(A)+0.5mg(B) | 1 Tablet | 32.98 |
| 2 | Buprenorphine (A) +Naloxone (B) | Tablet (Sub-lingual) 0.4mg(A)+0.1mg(B) | 1 Tablet | 10.54 |
| 3 | Buprenorphine | Tablet (Sub-lingual) 0.4mg | 1 Tablet | 8.41 |
| 4 | Tenofovir Alafenamide Fumarate (TAF) | Tablet 25mg | 1 Tablet | 43.59 |
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.